Additional Proxy Soliciting Materials (definitive) (defa14a)
July 02 2021 - 7:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
PROXY STATEMENT
PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant x
|
|
Check the appropriate box:
|
¨
|
Preliminary Proxy Statement
|
|
¨
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
¨
|
Definitive Proxy Statement
|
|
x
|
Definitive Additional Materials
|
|
¨
|
Soliciting Material Pursuant to sec. 240.14a-11(c) or sec. 240.14a-12
|
NEUBASE
THERAPEUTICS, INC.
(Name
of Registrant as Specified in Its Charter)
N/A
(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
¨
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined):
|
|
|
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
|
|
|
¨
|
Fee paid previously with preliminary materials.
|
|
¨
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and
the date of its filing.
|
|
(1)
|
Amount Previously Paid:
|
|
|
|
|
(2)
|
Form, Schedule or Registration State No.:
|
|
|
|
|
NeuBase Therapeutics, Inc.
Important Notice Regarding the
Availability of Proxy Materials
Stockholders Meeting to be held on
August 18, 2021
For Stockholders as of record on June 24, 2021
Have the 12 digit control number located in the shaded box above available
when you access the website and follow the instructions.
When requesting via the Internet or telephone you will need the 12 digit
control number located in the shaded box above.
* If requesting material by e-mail, please send a blank
e-mail with the 12 digit control number (located above)
in the subject line. No other requests, instructions OR
other inquiries should be included with your e-mail
requesting material.
NeuBase Therapeutics, Inc.
Meeting Type:
Date:
Time:
Place:
Annual Meeting of Stockholders
Wednesday, August 18, 2021
10:00 AM, Eastern Time
Annual Meeting to be held live via the Internet
please visit www.proxydocs.com/NBSE for more details.
You must register to attend the meeting online and/or participate at www.proxydocs.com/NBSE
SEE REVERSE FOR FULL AGENDA
INTERNET
www.investorelections.com/NBSE
TELEPHONE
(866) 648-8133
* E-MAIL
paper@investorelections.com
To order paper materials, use one of the following methods.
For a convenient way to view proxy materials
and VOTE go to www.proxydocs.com/NBSE
If you want to receive a paper or e-mail copy of the proxy material, you must request one. There
is no charge to you for requesting a copy. In order to receive a paper package in time for this
year's meeting, you must make this request on or before August 09, 2021.
This communication presents only an overview of the more
complete proxy materials that are available to you on the Internet.
This is not a ballot. You cannot use this notice to vote your
shares. We encourage you to access and review all of the important
information contained in the proxy materials before voting.
To view the proxy materials, and to obtain directions to attend
meeting, go to: www.proxydocs.com/NBSE
To vote your proxy while visiting this site, you will need the 12
digit control number in the box below.
Under United States Securities and Exchange Commission rules, proxy
materials do not have to be delivered in paper. Proxy materials can be
distributed by making them available on the internet.
P.O. BOX 8016, CARY, NC 27512-9903
|
|
NeuBase Therapeutics, Inc.
Annual Meeting of Stockholders
PROPOSAL
1 To elect two Class I Directors, Dov A. Goldstein, MD, and Eric I Richman, nominated by our Board of Directors, to serve until our 2024 Annual
Meeting of Stockholders and until their successors are duly elected and qualified.
1.01 Dov A. Goldstein, MD
1.02 Eric I. Richman
2. To ratify the selection of Marcum LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2021
3 To approve, on an advisory basis, the compensation paid to the Company's Named Executive Officers, as disclosed pursuant to Item 402 of
Regulation S-K, including the compensation tables and narrative discussion within the section of the Company's Proxy Statement entitled
"Executive Compensation."
4 To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE:
FOR ON PROPOSALS 1, 2 AND 3
|
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Aug 2024 to Sep 2024
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Sep 2023 to Sep 2024